Navigation Links
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Date:3/25/2008

PALO ALTO, Calif., March 25 /PRNewswire/ -- Anacor Pharmaceuticals today announced results from a Phase 2a clinical trial of AN2728, an investigational topical anti-inflammatory drug, in patients with psoriasis. The study met its primary endpoint and all secondary endpoints.

In 69 percent of patients, the area treated with AN2728 scored better at the end of therapy than the area treated with the vehicle ointment, compared with six percent of patients in whom the vehicle-treated areas were superior. These results were statistically significant (p<0.001). No drug-related safety issues were reported.

"The results of this study suggest that AN2728 can effectively treat psoriasis in a clinical setting. In addition, plaques treated with AN2728 continued to improve over the course of the 28 days of therapy, suggesting longer-term treatment may have an even greater effect," said Karl R. Beutner, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Anacor. "These results are encouraging for both AN2728 and our entire anti-inflammatory program."

AN2728 is a novel boron-containing small molecule that inhibits the release of pro-inflammatory cytokines including TNF-alpha, IL-12, and IL-23, known mediators of the inflammation associated with psoriasis.

The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of an ointment containing a 5% concentration of AN2728 with patient self-application. Patients with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. The study took advantage of this bilateral characteristic of psoriasis. In this trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on the opposite side with vehicle alone, twice a day for four weeks.

In addition to this Phase 2a study, two Phase 1b dose-ranging trials have investigated the effects of concentration and formulation
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
5. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ww.christmasseals.org to learn more, make a donat...SHINGTON, Nov. 17 Milli...month, courtesy of the American Lung Association. ...ual fundraising tradition dating back to 1907 when...culosis. , , "Most Americans alive today ...
(Date:11/18/2008)...E, Va., Nov. 18 Forty-t...ed at a November national forum to consider cuttin...c health and national economy from outbreaks of da...ed today. , , Among those innovations: , ...merican kitchen table that detects highly contagio...
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference 314 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 2Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 3Society for General Microbiology 161st Meeting University of Edinburgh 217 1Society for General Microbiology 161st Meeting University of Edinburgh 217 2A drug sensitive traffic cop tells potassium channels to get lost 364 1A drug sensitive traffic cop tells potassium channels to get lost 364 2
..., Germany, May 31, 2007- Results from various,clin...n patients,with advanced hepatocellular carcinoma,...tablets will be presented at the Annual,Meeting of...in,Chicago, USA from June 1 - 5, 2007. , On this o...ts,will be held on June 4, 2007. Starting at aroun...
...f Abstracts Reflects Continued Growth of Eisai,s,C...1, 2007 /PRNewswire/ -- Eisai,announced today that...eir oncology pipeline compounds have been accepted...cal Oncology (ASCO),annual meeting. ASCO takes pla...ts reveal a growing and diverse oncology clinical,...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:11/21/2008)... Nov. 21 Heska Corporati...ent at the New York Society of,Security Analysts,...ce on,December 2, 2008 at 1177 Avenue of the Amer... is scheduled to begin at 9:35 a.m. Eastern Time (...a live webcast and for two weeks,following the pr...
(Date:11/21/2008)...remain cautious about future antibiotic resistance...21 (HealthDay News) -- People with moderate to sev...ay be able to reduce the frequency of exacerbation...ic, a new report says. , The study, published ...ournal of Respiratory and Critical Care Medicine ,...
(Date:11/21/2008)... The University of Tex...ing of a collaborative effort to eradicate breast ...t Cancer Awareness and Research of the Americas to... the United States, and Vivian Fernandez de Torrij.... D. Anderson in the initiative are the U.S. Depar...
(Date:11/21/2008)...rs Intend To Vigorously Protect Investment And Res... 21 Dr. Stephen Joffe, ...ent to their Schedule 13D with the U.S. Securities...led a 13D disclosing ownership of 11.4% of LCA-Vis...ikPlus fixed-site laser vision correction centers ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...y has selected Indian ministry of health and famil...or its "unrelenting stance on health promotion and... Welfare Anbumani Ramadoss will receive the award ...ce on Tobacco in Washington DC Friday, a ministry ...
...th African Indian Siamese twins are doing well and...nielle and Danika Lowton, born on June 21 at the A...ng their oral feeds. "They are gaining weight and...the Post newspaper quoted Wian Stander, head of th...
... live-saving stem cells, seven banks of umbilical ...st of the series will open in Gurgaon this// month...ks International, a US body, and R.J. Corporation ... will invest Rs.1 billion to build the seven repos...
...t was smuggled into the United States was found in...s over the past month. Michigan health// officials...to official reports there is no sign that the froz...rails intact, had been contaminated with the deadl...
Other Medicine News:Health News:First Cord Blood Bank in North India to be Opened in Gurgaon 2
...versatile means of sectioning fresh or fixed, anim...g blade principle which allows sectioning without ... the alteration of morphology, the destruction of ...nherent in freezing or embedding procedures are th...
...ovides a versatile means of sectioning fresh or fi... vibrating blade principle which allows sectioning...rtifacts, the alteration of morphology, the destru...effect inherent in freezing or embedding procedure...
...provides a versatile means of sectioning fresh or ... a vibrating blade principle which allows sectioni... artifacts, the alteration of morphology, the dest...s effect inherent in freezing or embedding procedu...
Instrument Cover for Vibratome.
Medicine Products: